Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) associated with poor prognosis. Animal models of MCL are scarce. We established and characterized various in vivo models of metastatic human MCL by tail vein injection of either primary cells isolated from patients with MCL or established MCL cell lines (Jeko-1, Mino, Rec-1, Hbl-2, and Granta-519) into immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice. MCL infiltration was assessed with immunohistochemistry (tissues) and flow cytometry (peripheral blood). Engraftment of primary MCL cells was observed in 7 out of 12 patient samples. The pattern of engraftment of primary MCL cells varied from isolated involvement of the spleen to multiorgan infiltration. On the other hand, tumor engraftment was achieved in all five MCL cell lines used and lymphoma involvement of murine bone marrow, spleen, liver, and brain was observed. Overall survival of xenografted mice ranged from 22±1 to 54±3 days depending on the cell line used. Subsequently, we compared the gene expression profile (GEP) and phenotype of the engrafted MCL cells compared with the original in vitro growing cell lines (controls). We demonstrated that engrafted MCL cells displayed complex changes of GEP, protein expression, and sensitivity to cytotoxic agents when compared with controls. We further demonstrated that our MCL mouse models could be used to test the therapeutic activity of systemic chemotherapy, monoclonal antibodies, or angiogenesis inhibitors. The characterization of MCL murine models is likely to aid in improving our knowledge in the disease biology and to assist scientists in the preclinical and clinical development of novel agents in relapsed/refractory MCL patients. Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) characterized by the chromosomal translocation t(11;14)(q13;q32) leading to overexpression of cyclin D1. 1 Apart from this canonical aberration, MCL may harbor a large number of recurrent cytogenetic changes that further deregulate cell cycle machinery (for example, deletion of 9p21 (CDKN2A) and amplification of 12q13 (CDK4)) or interfere with cellular response to DNA damage (for example, alterations of 11q22-q23 (ATM), 17p13 (TP53) and overexpression of MDM2). 2-5 MCL is associated with poor prognosis. 6, 7 In order to improve the outcome of MCL patients, the rational development and preclinical/clinical testing of new agents are necessary. Reliable and reproducible in vivo models of MCL are thus urgently needed. In vivo models have several advantages over in vitro approaches. For example, they enable the study of MCL biology in its microenvironment, including engraftment, growth rate, spread patterns, or tumor associated neovascularization.
Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) characterized by the chromosomal translocation t(11;14)(q13;q32) leading to overexpression of cyclin D1. 1 Apart from this canonical aberration, MCL may harbor a large number of recurrent cytogenetic changes that further deregulate cell cycle machinery (for example, deletion of 9p21 (CDKN2A) and amplification of 12q13 (CDK4)) or interfere with cellular response to DNA damage (for example, alterations of 11q22-q23 (ATM), 17p13 (TP53) and overexpression of MDM2). [2] [3] [4] [5] MCL is associated with poor prognosis. 6, 7 In order to improve the outcome of MCL patients, the rational development and preclinical/clinical testing of new agents are necessary. Reliable and reproducible in vivo models of MCL are thus urgently needed. In vivo models have several advantages over in vitro approaches. For example, they enable the study of MCL biology in its microenvironment, including engraftment, growth rate, spread patterns, or tumor associated neovascularization.
In addition, in vivo models are preferable for the testing of agents that cannot be reliably tested in vitro (for example, monoclonal antibodies, immunomodulatory drugs, prodrugs, inhibitors of B-cell receptor signaling, or inhibitors of angiogenesis). Mouse models of MCL reported in the literature include two large groups: (1) genetically engineered mice predisposed to develop a MCL-like disease and (2) immunodeficient mice capable of bearing human MCL xenografts. [8] [9] [10] [11] Recently, characterization of a mouse xenograft model using primary MCL cells was reported; however, it was unfortunately technically demanding and difficult to implement. 11 Currently, the most widely used MCL xenograft model utilizes the subcutaneous injection of established MCL cell lines into immunodeficient mice. [12] [13] [14] [15] To further improve on the current available MCL mouse models, we established and characterized several reproducible metastatic mouse models of human MCL by the inoculation of human primary MCL cells or MCL cell lines (Jeko-1, Mino, Rec-1, Granta-519, and Hbl-2) via tail vein injection (i.v.) into an immunodeficient mice NOD.Cg-Prkdc scid
Il2rg
tm1Wjl /SzJ (non-obese diabetic, interleukin-2 receptor gamma common chain null), commonly referred to as NOD-SCID-gamma (NSG) mice. We demonstrated that MCL cells obtained ex vivo from various infiltrated murine organs displayed distinct changes in gene expression profile (GEP), immunophenotype, and sensitivity to cytotoxic agents compared with in vitro growing MCL cells. Our findings suggest that engraftment of MCL cells into immunodeficient mice leads to clonal selection and illustrate the complex interaction between lymphoma cells and its host. Moreover, given the different responses to standard chemotherapy agents observed between MCL cells and MCL isolated following in vivo engraftment our work further stress the need to use both in vitro and in vivo preclinical models in the evaluation of novel agents for B-cell lymphoma patients.
MATERIALS AND METHODS MCL Cell Lines
MCL cell lines Jeko-1, Rec-1, and Granta-519 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ). The Mino cell line was obtained from American Tissue Culture Collection (ATCC), and the Hbl-2 cell line was a kind gift from Professor Martin Dreyling (University of Munich, Munich, Germany).
Primary MCL Cells
Primary MCL cells were obtained from the peripheral blood, bone marrow (BM), lymph node, or pleural effusion of MCL patients. Mononuclear cells were isolated by the standard Ficoll-Hypaque gradient centrifugation, and frozen in heat inactivated fetal bovine serum supplemented with 10% dimethyl sulfoxide (DMSO).
Samples were obtained after informed consent according to the Declaration of Helsinki. This work was approved by the Ethics committee of the General University Hospital in Prague.
Immunodeficient Mice
The NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice (referred to as NSG mice) were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA). All animals were housed and maintained in a pathogen-free environment in individually ventilated cages and provided with sterilized food and water. The experimental design was approved by the institutional animal care and use committee.
Xenograft Experiments Using Primary MCL Cells
Eight-to twelve-week-old female NSG mice were used for all experiments. On day 1 the mice were sublethally irradiated (2.5 Gy) and subsequently inoculated via tail vein injection with freshly thawed primary MCL cells (10-80 Â 10 6 ). Upon the development of hint-leg paralysis or generalized inability to thrive, animals were euthanized by cervical dislocation. Mice that showed no signs of lymphoma engraftment were killed 60 days following tumor cell inoculation. Selected murine organs were subjected to immunohistochemical (IHC) analysis to assess organ infiltration with human cells (see in detail further).
Xenograft Experiments Using MCL Cell Lines
The mice were injected with 1 Â 10 6 MCL cells (Granta-519, Hbl-2, and Jeko-1) or 10 Â 10 6 MCL cells (Rec-1 and Mino) via tail vein injection. Two animals from each cohort were killed at four different time points (designated T1, T2, T3, and T4). T1 was set as the midpoint between the day of tumor inoculation (Day 0) and the estimated overall survival (OS). OS was defined as the time between tumor cell inoculation (Day 0) and the time of development of limb paralysis (T4). T2 and T3 were set in between of the T1 and T4 time points so that they represented one-third and twothirds of the interval between T1 and T4, respectively. At T4 time point, peripheral blood samples were collected following anesthesia with ketamine-xylazin by retro-orbital exsanguination and before euthanasia. Then, red cells were lyzed using a lysis buffer (BioLegend, USA) and the samples were submitted to flow cytometric analysis (see section Flow cytometry analysis).
IHC Analysis
Once the animals reached T4, necropsy studies were performed. Murine organs were removed, fixed in 4% formalin for 7 days, cut into tissue blocks, embedded in paraffin, and sectioned into transversal and longitudinal 6-7 mm thick slices. Sections were stained with hematoxylin and eosin, Masson's blue trichrome, and Gömöri impregnation. 16 
Ex Vivo Isolation of MCL Cells
The murine organs were homogenized using 45 mM cell strainers (Becton Dickinson). Bone marrow was flushed from murine femurs with 3 ml of sterile PBS into a sterile container and passed through the 45-mM cell strainer. Human MCL cells were isolated from homogenized murine organs (BM, liver (L), spleen (S), lymph node-like tumors (T)) by magnetic cell sorting using an anti-human-CD45 micro beads (Miltenyi Biotec) at T4 time point. The purity of MCL population after sorting was 495% in all cases as verified using flow cytometry. MCL cells cultured in parallel in vitro served as controls (CTRL cells) and were processed in the same way (that is, they were sorted on magnetic columns using anti-CD45 microbeads) to eliminate any potential bias caused during the magnetic cell sorting. Ex vivo obtained CD45-sorted cells were either directly used for experiments (designated BM, S, L, or T) or they were recultured for 14 days in vitro (designated BM-EX, S-EX, L-EX, and T-EX), after which they were again CD45-sorted and used for experiments.
GEP
Mino and Jeko-1 cell lines were used for GEP studies. Total mRNA was isolated from in vitro cultured or ex vivo-sorted MCL cells in RNA later solution using RNeasy Mini Kit (Qiagen, Hilden, Germany). Quality of RNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technology).
Extracted RNA was amplified using the Illumina RNA Amplification Kit (Ambion). Amplified RNA was hybridized to the IlluminaHumanRef-12 BeadChips (Mino) and IlluminaHumanRef-8 Bead Chips (Jeko-1). Differences in gene expressions between MCL cells obtained from different murine organs were investigated. Data analysis was performed in R-software 17 using Bioconductor 18 repository packages. Particularly, we used the bead array package for data extraction. 19 We further analyzed Illumina expression data on the level of unsummarized beads. We performed quantile normalization and t-test to find significantly differently expressed mRNAs between two states of our interest. A multiple testing correction was performed using the Benjamini and Hochberg method (Benjamini and Hochberg, 1995). The filtered group of genes with fold change greater/ lower than ±1.2, and adjusted P-values o0.05 were annotated and arranged into biologically relevant categories using The Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov).
Flow Cytometry Analysis
Flow cytometry was performed on BD FACS Canto II and evaluated using FCS express software (version 3). The following directly conjugated antibodies were used in this study: an anti-human allophycocyanin (APC)-conjugated anti-CD44 (MEM-85), a phycoerythrin (PE)-conjugated anti-CD45R (MEM-28) (Exbio, Czech Republic), a PE-conjugated anti-CD31 (PECAM-1; WM59), a peridinin-chlorophyll protein Cyanine 5.5 (PerCP-Cy5.5)-conjugated anti-CD45 (2D1), a fluorescein isothiocyanate-labeled anti-CD20 (2H7), an APC-labeled anti-CD184 (CXCR4)-APC (12G5), a PE-conjugated anti-CD197 (CCR7; G043H7), and PE-conjugated anti-podoplanin (NC-08; BioLegend).
Cell Proliferation Assays MCL cells were plated at a cell density of 5000 cells per 0.3 ml and exposed to the following chemotherapy agents: cytarabine or cisplatin. Cell proliferation was measured using the WST-8-based Quick Cell Proliferation Assay Kit (BioVision) according to the manufacturer's instructions.
Re-Transplantation Experiments
MCL cells were obtained from the BM of NSG mice inoculated with 10 Â 10 6 Mino or 1 Â 10 6 Jeko-1 cells (primary recipients). MCL purification was achieved using CD45 microbeads. Subsequently, isolated MCL cells were inoculated via tail vein injection into additional non-radiated NSG mice (secondary recipients). NSG mice inoculated with in vitro growing MCL cells (CTRL cells) were used as controls.
Similar experiments were performed using cells isolated from MCL patients. For these experiments, primary MCL cells were isolated from infiltrated organs (spleen) of NSG mice (primary recipients). No cell sorting was used; instead, unsorted MCL cells were obtained ex vivo from the infiltrated spleen by passing the spleen through the 45-mM cell strainer, washed in PBS, and injected into sublethally irradiated NSG mice (secondary recipients).
Experimental Single-Agent Therapy of MCL Xenografts
To study the effects of therapeutic interventions in our in vivo models, NSG mice were inoculated with 10 Â 10 6 Mino, 1 Â 10 6 Jeko-1, or 10 Â 10 6 NEMO cells and divided into several treatment cohorts (five to eight animals/cohort). Treatment started 5 days post inoculation and continued until T4. Control group received sterile PBS. Treatment groups received the following single-agent treatments: (1) cyclophosphamide (3 mg/dose) once weekly, (2) gemcitabine (10 mg/dose) once weekly, (3) fludarabine (1 mg/dose) for 3 consecutive days every week, (4) temsirolimus (1 mg/dose) once weekly, (5) bortezomib (25 mg/dose) twice weekly, (6) rituximab (0.3 mg/dose) twice weekly, (7) bevacizumab (0.3 mg/dose) twice weekly, (8) lenalidomide (1 mg/dose) daily on working days until T4. All agents were administered intraperitoneally (i.p.). Differences in survival between treatments groups were evaluated using Kaplan-Meier survival estimates, which were set-up using Graph-Pad Prism software.
RESULTS

Mouse Models of Human MCL Using Primary MCL Cells
Primary MCL cells (n ¼ 12) were isolated from the peripheral blood (PB, n ¼ 8), PB and BM (n ¼ 2), involved lymph node (n ¼ 1) or pleural effusion (PE) (n ¼ 1) of MCL patients. Most of the patients presented with the classic variant MCL (n ¼ 8). In addition, MCL cells were isolated from pleomorphic (n ¼ 1) or blastoid variant (n ¼ 3) MCL. Cells were isolated from previously untreated patients (n ¼ 10) or at the time of relapse (n ¼ 2). Most patients had high MCL International Prognostic Index (MIPI) score (n ¼ 11) and had adverse cytogenetics defined as either deletion of TP53 or deletion of ATM (n ¼ 9). Engraftment of cyclin D1 þ cells was observed in 7 out of 12 patient-derived cell suspensions injected into NSG mice (Table 1 Table 2a ) over time. Whereas involvement of the CNS was observed in animals injected with all five MCL cell lines, infiltration of the PB and kidneys was variable (Table 2b ). Animals inoculated with Jeko-1 and Rec-1 cells often developed enlargement of the ovaries due to lymphoma infiltration (Figure 2b , Supplementary Figure 2b) . Interestingly, mice engrafted with Mino cells frequently developed lymph node-like tumors in the axillary and submandibular regions, or 'extranodal' tumors (intraabdominal, intra-orbital, or subcutaneous). In addition, mice with bulky intra-abdominal tumors often had malignant ascites (confirmed by FACS, data not shown). IHC analysis of the enlarged submandibular tumor by Gömöri impregnation revealed collagen 3-rich lymph node-like structure composed predominantly of human MCL B cells (Figure 2a ). Mice injected with Hbl-2 cells typically developed hint-leg paralysis at T4 (Figure 2c ). Signs of terminal disease (weight loss and generalized inability to thrive) were observed in mice injected with Granta-519, Jeko-1, Mino, and Rec-1 cell lines by T4. The extent of infiltration of murine tissues with all five MCL cell lines during T1-T4 time points are given in Table 2 . Weights of the murine spleen and liver at T4 correlated with the extent of organ infiltration and are given in Table 2b .
GEP Changes of Ex Vivo Obtained MCL Cells when Compared with In Vitro growing Cell Line Controls
GEP of MCL cells obtained ex vivo from different murine organs (BM, S, L, and T) clustered together and displayed complex GEP changes compared with in vitro growing controls (CTRL; Figure 3a) . Interestingly, GEP signature of ex vivo MCL cells isolated from NSG mice cultured for 14 days in vitro reverted to the original MCL in vitro signature (Figure 3a) . In addition, the filtered group of genes with fold change greater than 1.2 and adjusted P-value o0.05 were annotated and arranged into biologically relevant categories using the DAVID database. B-cell receptor signaling ( Figure 3) . There were no differences in the sensitivity to cisplatin or cytarabine between T and CTRL Mino cells (data not shown). Jeko-1 BM cells were more sensitive to cisplatin (approximately twofold) and cytarabine (approximately fourfold) than CTRL Jeko-1 cells (Supplementary Figure 3) . Jeko-1 S cells were more sensitive to cisplatin (approximately twofold), but not to cytarabine, compared with CTRL Jeko-1 cells (data not shown). There were no differences in the sensitivity to cisplatin or cytarabine between L and CTRL Jeko-1 cells (data not shown).
Secondary Recipients Xenografted with MCL Cells Obtained Ex Vivo from the Bone Marrow of Primary Recipients have Significantly Shorter OS Compared with Mice Xenografted with CTRL Cells
On the basis of the results obtained from the microarray and flow cytometry experiments, we assumed that MCL cells growing in vivo display complex changes of GEP and immunophenotype, and that those changes may reflect the MCL cell adaptation to the murine microenvironment. We thus decided to test the ability of the ex vivo obtained MCL cells to re-engraft into secondary recipients and to evaluate Mouse models of mantle cell lymphoma M Klanova et al changes in disease behavior. Of interest, the OS of secondary recipient NSG mice xenografted with 0.5 Â 10 6 Mino BM cells was shorter than secondary recipients inoculated with Mino CTRL cells (65.2±3.6 vs 84±8 and days, respectively (Po0.001)) (Supplementary Figure 4) . Similarly, the OS of secondary recipients inoculated with 0.8 Â 10
6 Jeko-1 CTRL was 41.2 ± 2.6 vs 33.8 ± 2.8 for secondary recipients of Jeko-1 BM cells (Po0.001; Supplementary Figure 4) .
Experimental Therapy of MCL-Xenografted Mice
The established in vivo models of MCL, both cell line-based (Mino-and Jeko-1-xenografted mice) and primary cell-based Rec-1 BM 34.9 ± 2.9 45.2 ± 3.2 57.0 ± 2.9 59.0 ± 6.3 Abbreviations: BM, bone marrow; MCL, mantle cell lymphoma; NSG, NOD-SCID-gamma; PB, peripheral blood.
Mouse models of mantle cell lymphoma M Klanova et al (NEMO-bearing mice) were used as tools for the preclinical assessment of experimental therapeutic approaches. Apart from the standardly used chemotherapy drugs (fludarabine, gemcitabine, and bortezomib), the mice were treated with agents, the antitumor activity of which cannot be reliably evaluated in vitro including monoclonal antibodies (rituximab and bevacizumab), pro-drugs (cyclophosphamide), cell signaling inhibitors (temsirolimus), or immunomodulatory agents (lenalidomide). In vivo treatment of MCL inoculated NSG mice with gemcitabine (Gem), temsirolimus (Tem), cyclophosphamide (Cyc), and rituximab (Rit) significantly prolonged OS in all three tested xenograft models (Po0.05). Fludarabine (Flu) significantly prolonged OS in Jeko-1 and Mino (Po0.05), but not in NEMO-xenografted mice. Bevacizumab (Bev) significantly (Po0.05) prolonged OS in Jeko-1 and NEMO, but not in Mino-xenografted mice. Lenalidomide (Len) significantly prolonged OS only in NEMO-bearing mice, whereas bortezomib (Bor) failed to prolong OS in any of the three tested mouse models at the dose/schedule tested ( Figure 4) . . We also demonstrated that in occasional cases (VFN-1) the engrafted primary MCL cells can be harvested (ideally from the enlarged spleen) and either frozen or directly used for re-transplantation into secondary recipients. Despite the fact that selected primary MCL cells do engraft in immunodeficient NSG mice, it must be taken in mind that most of the currently published preclinical therapies are carried out using established MCL cell line xenografts, usually after subcutaneous injection, whereas i.v. xenotransplantations are less frequently used. In addition, little is known about the way of engraftment and/or spread of the lymphoma cells in the murine organism upon xenotransplantation, or about their potential phenotype changes induced by murine microenvironment.
In this study we thoroughly characterized engraftments of five widely used MCL cell lines (Mino, Jeko-1, Granta-519, Hbl-2, and Rec-1) in the immunodeficient NSG mice. In contrast to primary MCL cells, the engraftment of which occurred almost exclusively in the spleen, the principal site of engraftment of all MCL cell lines appeared to be the BM, from where MCL cells apparently disseminated to the spleen, liver, and later in the course of disease to other murine organs and tissues, including the CNS and kidneys. Involvement of other organs, including ovaries, lymph nodes, or PB, appeared to be MCL cell line-specific. The median OS of mice xenografted with MCL cells ranged from 22±1 to 54 ± 3 days. By far, the most biologically aggressive MCL cell line was Granta-519, despite the fact that it demonstrated the slowest proliferation rate in vitro of all five MCL cell lines (data not shown). The reason for the observed diversity in the biological aggressiveness of the five MCL cell lines remained largely elusive.
Interestingly, GEP and flow cytometry experiments unveiled that MCL cells growing in vivo in different murine organs had different gene expression signatures and immunophenotypes (in vivo signature) compared with in vitro growing MCL cells (in vitro signature). Genes coding for chemokines and chemokine receptors, including CXCL10, CCL3, CCL3L3, CCL4L1, CCL4L2, CXCR4, or CCR7, belonged to the most deregulated genes in MCL cells in vivo compared with cells in vitro. These results highlight the influence of the tumor microenvironment to the biology of MCL. 'Oxidative phosphorylation' and 'B-cell receptor signaling' belonged to the most downregulated and upregulated functional clusters, respectively. We assume that upon engraftment, MCL cells undergo complex changes of gene and protein expression as a result of adaptation to the microenvironment of murine tissues, including cell-cell interactions, hypoxia, lack of nutrients, engagement of integrin receptors and so on. Not surprisingly, mice re-transplanted from primary to secondary mouse recipients had significantly shorter OS compared with mice xenografted with CTRL cells.
Finally, we confirmed that the mouse models could be used for preclinical assessment of current or novel therapies. Curiously, we noticed a marked difference between the tested in vitro sensitivity of MCL cells to some anticancer agents and rather poor outcome when using the same agent for the in vivo therapy of MCL-xenografted mice. For example, the in vitro lethal dose (LD100) of Jeko-1 cells to gemcitabine and bortezomib was 10 and 16 nM, respectively. Despite the excellent in vitro sensitivity to both agents, bortezomib therapy of Jeko-1-xenografted mice failed to improve OS, whereas therapy with high doses of gemcitabine did not lead to eradication of the lymphoma. We suppose that the observed discrepancy between in vitro sensitivity (excellent) and in vivo efficacy (poor) of many of the tested cytotoxic agents could be explained by the phenotypic changes associated with the engraftment and described in detail above. We also observed that immunomodulatory agent lenalidomide, the anticancer activity of which is based on the modulation of complex interactions of lymphoma cells with the microenvironment, failed to prolong survival of MCL cell line-xenografted mice (Mino and Jeko-1), but significantly prolonged survival of NEMO-bearing mice. In sharp contrast to Jeko-1 and Mino cells, NEMO cells (derived from VFN-1 patient sample) underwent rapid apoptosis upon ex vivo culture (after isolation from the infiltrated murine spleen), which clearly emphasizes the continuous dependence of NEMO cells on murine microenvironment for survival (data not shown). We suppose that targeted disruption of these pro-survival bonds by lenalidomide might be responsible for the observed prolongation of OS of NEMObearing mice. NEMO-xenografted mice thus represent an appropriate in vivo system for the study of lenalidomide biology.
In conclusion, we established and characterized several mouse models of human MCL using both primary MCL cells and MCL cell lines. We demonstrated that the engrafted MCL cells are biologically distinct populations because they display complex changes in gene expression, immunophenotype, and sensitivity to cytotoxic agents compared with in vitro growing MCL cell lines. These findings may have extensive implications for preclinical research.
